Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 10/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675162 | 0.88 | MAT2A (0.44) | CDC7KITFPR2SCN9A | |
| SCHEMBL4078297 | 0.77 | MAT2A (0.47) | KITACVR1FPR2SCN9A | |
| SCHEMBL4084126 | 0.77 | MAT2A (0.47) | KITACVR1FPR2SCN9A | |
| SCHEMBL4083507 | 0.76 | MAT2A (0.43) | ACVR1FPR2SCN9A | |
| SCHEMBL7751006 | 0.75 | MAT2A (0.46) | ACVR1FPR2SCN9A | |
| SCHEMBL4077720 | 0.75 | MAT2A (0.47) | ACVR1FPR2SCN9A | |
| SCHEMBL7749780 | 0.75 | MAT2A (0.47) | ACVR1FPR2SCN9A | |
| SCHEMBL4074751 | 0.75 | MAT2A (0.42) | ACVR1FPR2SCN9A | |
| SCHEMBL7751002 | 0.74 | MAT2A (0.43) | ACVR1FPR2SCN9A | |
| SCHEMBL4078860 | 0.73 | ACVR1 (0.43) | ACVR1FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731520-A1 | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 | OSI Pharmaceuticals, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-6664252-B2 | (6-aryl-pyrrolo(2,3-d)pyrimidin-4-yl)amine derivatives; treating Parkinson's disease and diseases associated with locomotor activity, vasodilation, platelet inhibition, neutrophil superoxide generation, cognitive disorders, etc. | OSI PHARMACEUTICALS, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | CDC7 3330/4885KIT 3368/4885CCNB2 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.